【Invitation】API China - Haibu invites you to the "2024 New Drug Research and Development and Commercialization Path Exploration Conference"
Classification:
Recent Events
Release time:
2024-05-14
To meet the new development needs of the industry, the 88th National Pharmaceutical Trade Fair (PHARMCHINA), the 90th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Trade Fair (APIChina), and the 2024 China International Health Nutrition Expo (NHNE) will be held from May 15 to 17, 2024, inPHARMCHINA. It is expected to attract nearly 4,000 enterprises from the domestic and international pharmaceutical and health nutrition industries to participate in the exhibition, hold more than 100 conference activities, and the number of attendees is expected to exceed 150,000.Shanghai National Exhibition and Convention Center举办。预计将吸引来自海内外医药及健康营养产业近4000家企业参展，举办会议活动100余场，参会观众有望突破15万人次。
Conference Background
On the occasion of this "three exhibitions held together", the "2024 New Drug R&D and Commercialization Path Exploration Conference" organized by China National Pharmaceutical Group Co., Ltd. and hosted by Yaozhi Network will emerge. The conference will be showcased simultaneously at the 88th National Pharmaceutical Trade Fair, API's 90th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Trade Fair, and the 2024 China International Health Nutrition Expo.Yaozhi Network主办，药智传媒承办的“2024新药研发与商业化路径探索大会”应运而生，大会将在第88届全国药品交易会、API第90届中国国际医药原料药/中间体/包装/设备交易会、2024中国国际健康营养博览会上同步亮相。
This conference will gather well-known domestic pharmaceutical companies, research institutions, investment institutions, and other parties to jointly explore the latest trends in new drug R&D, technological innovation, and market opportunities. Through various forms such as keynote speeches and project roadshows, it aims to provide a broad platform for communication and cooperation for participants, accelerate the transformation of scientific research achievements, and promote deep integration and collaborative development of the pharmaceutical industry chain.
Conference Time
May 16, 2024 09:00-17:00
Conference Venue
National Exhibition Center (Shanghai)
Hall 7.2 on-site conference room
(Beijing Haibu Pharmaceutical Technology Co., Ltd.) was established in 2005 as a high-tech enterprise with "chemical drug R&D" as its core capability. It has a Beijing R&D center, an active pharmaceutical ingredient (API) and formulation pilot verification center, a GMP industrial production base, mainly engaged in CRO services for APIs and formulations, MAH joint licensing holding, API-related declarations as well as commercial supply of pharmaceutical intermediates.在化学原料药、口服固体、液体制剂、无菌注射剂、外用制剂等多种剂型的研发转产、注册申报等方面经验丰富。研发产品涉及抗肿瘤、抗抑郁、抗癫痫、抗焦虑、心脑血管、消化系统、呼吸系统等多个适应症领域。
(Beijing Haibu Pharmaceutical) has rich experience in R&D transfer production registration declaration in various dosage forms such as chemical raw materials drugs, oral solids, liquid preparations, sterile injections, external preparations etc. The R&D products involve multiple indications including anti-tumor drugs, anti-depressants, anti-epileptics, anti-anxiety drugs cardiovascular diseases digestive system respiratory system etc.
Beijing Hope Pharmaceutical Co., Ltd.
